Last reviewed · How we verify

aspirin and/or clopidogrel — Competitive Intelligence Brief

aspirin and/or clopidogrel (aspirin and/or clopidogrel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent. Area: Cardiovascular.

marketed Antiplatelet agent COX (aspirin); P2Y12 receptor (clopidogrel) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

aspirin and/or clopidogrel (aspirin and/or clopidogrel) — Asan Medical Center. Aspirin and clopidogrel are antiplatelet agents that inhibit platelet aggregation through different pathways to prevent blood clots.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
aspirin and/or clopidogrel TARGET aspirin and/or clopidogrel Asan Medical Center marketed Antiplatelet agent COX (aspirin); P2Y12 receptor (clopidogrel)
Plavix clopidogrel Generic (originally Sanofi/BMS) marketed Thienopyridine antiplatelet agent Cytochrome P450 2B6, P2Y purinoceptor 12, Sodium-dependent serotonin transporter 1997-11-17
Aspirin acetylsalicylic acid Bayer AG marketed NSAID, Antiplatelet agent Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3 1899-03-06
Aspirin (acetylsalicylic acid) Aspirin (acetylsalicylic acid) Swedish Medical Center marketed Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
aspirin + clopidogrel + celecoxib aspirin + clopidogrel + celecoxib Seoul National University Hospital marketed Antiplatelet agent combination with NSAID COX-1, P2Y12 receptor, COX-2
prasugrel/bivalirudin prasugrel/bivalirudin I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio marketed Antiplatelet agent + Direct thrombin inhibitor combination P2Y12 receptor (prasugrel); Thrombin (bivalirudin)
Clopidogrel only Clopidogrel only Seung-Jung Park marketed P2Y12 receptor antagonist / Thienopyridine antiplatelet agent P2Y12 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent class)

  1. Asan Medical Center · 1 drug in this class
  2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
  3. Beijing Tiantan Hospital · 1 drug in this class
  4. Centre Hospitalier Universitaire de Saint Etienne · 1 drug in this class
  5. China National Center for Cardiovascular Diseases · 1 drug in this class
  6. Hospital Israelita Albert Einstein · 1 drug in this class
  7. Icahn School of Medicine at Mount Sinai · 1 drug in this class
  8. PLx Pharma · 1 drug in this class
  9. Sichuan Provincial People's Hospital · 1 drug in this class
  10. The George Institute for Global Health, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). aspirin and/or clopidogrel — Competitive Intelligence Brief. https://druglandscape.com/ci/aspirin-and-or-clopidogrel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: